Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Oct 02, 16:00
Forte Biosciences Enterprise Value : 1.378B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.378B |
| October 01, 2026 | 1.378B |
| September 30, 2026 | 1.378B |
| September 29, 2026 | 1.378B |
| September 28, 2026 | 1.378B |
| September 25, 2026 | 1.378B |
| September 24, 2026 | 1.378B |
| September 23, 2026 | 1.378B |
| September 22, 2026 | 1.378B |
| September 21, 2026 | 1.378B |
| September 18, 2026 | 1.378B |
| September 17, 2026 | 1.378B |
| September 16, 2026 | 1.378B |
| September 15, 2026 | 1.378B |
| September 14, 2026 | 1.378B |
| September 11, 2026 | 1.378B |
| September 10, 2026 | 1.378B |
| September 09, 2026 | 1.378B |
| September 08, 2026 | 1.378B |
| September 04, 2026 | 1.378B |
| September 03, 2026 | 1.378B |
| September 02, 2026 | 1.378B |
| September 01, 2026 | 1.378B |
| August 31, 2026 | 1.378B |
| August 28, 2026 | 1.378B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.378B |
| August 26, 2026 | 1.378B |
| August 25, 2026 | 1.378B |
| August 24, 2026 | 1.378B |
| August 21, 2026 | 1.377B |
| August 20, 2026 | 1.376B |
| August 19, 2026 | 1.377B |
| August 18, 2026 | 1.376B |
| August 17, 2026 | 1.376B |
| August 14, 2026 | 1.375B |
| August 13, 2026 | 1.376B |
| August 12, 2026 | 1.374B |
| August 11, 2026 | 1.376B |
| August 10, 2026 | 1.375B |
| August 07, 2026 | 1.374B |
| August 06, 2026 | 1.375B |
| August 05, 2026 | 1.371B |
| August 04, 2026 | 1.370B |
| August 03, 2026 | 1.371B |
| July 31, 2026 | 1.370B |
| July 30, 2026 | 1.378B |
| July 29, 2026 | 1.369B |
| July 28, 2026 | 1.372B |
| July 27, 2026 | 1.368B |
| July 24, 2026 | 923.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| argenx SE | 56.82B |
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.33M |
| Total Expenses (Quarterly) | 23.33M |
| EPS Diluted (Quarterly) | -0.9808 |
| Earnings Yield | -6.66% |
| Normalized Earnings Yield | -6.663 |